Mitragynine and 7-Hydroxymitragynine: Bidirectional Effects on Breathing in Rats
Julio D. Zuarth GonzaleziD, Alexandria K. RagsdaleiD, Sushobhan MukhopadhyayiD, Christopher R. McCurdyiD, Lance Richard McMahoniD, Samuel ObengiD, Jenny L. WilkersoniD
Abstract
The use of kratom as an alternative to conventional opioids has surged, driven largely by anecdotal reports of its efficacy for pain relief and opioid withdrawal management. The growing prevalence of kratom products enriched with 7-hydroxymitragynine (7-HMG), an active metabolite of mitragynine (MG), necessitates evaluating the respiratory effects of these alkaloids and determining if naloxone reverses their potential respiratory depressant effects. Respiratory parameters were measured in awake, freely moving female and male Sprague-Dawley rats using whole body plethysmography. To minimize handling-induced artifacts and ensure precise respiratory recordings, drugs were administered intravenously. Morphine and 7-HMG induced significant respiratory depression, evidenced by reductions in breathing frequency, tidal volume, and minute volume. In contrast, MG administration unexpectedly increased respiratory frequency. Naloxone fully reversed the respiratory depression induced by both morphine and 7-HMG but did not alter the respiratory stimulant effects produced by MG. These findings demonstrate that 7-HMG exhibits significant respiratory depressant properties similar to classical opioids, and importantly, such depressant effects are effectively antagonized by naloxone. Conversely, MG exerts respiratory stimulant effects through mechanisms independent of opioid receptor pathways. Collectively, these data highlight crucial pharmacological distinctions between kratom alkaloids, underscoring the risk associated with high 7-HMG-containing kratom products and suggesting that the predominant alkaloid MG may offer a safer respiratory profile. Significance StatementThe prevalence of kratom products containing 7-hydroxymitragynine (7-HMG), a {micro}-opioid receptor agonist, underscores the need to evaluate respiratory effects of kratom-related alkaloids and their reversal by naloxone. 7-HMG induced significant respiratory depression comparable to morphine, which was reversed by naloxone. Conversely, mitragynine, kratoms most abundant alkaloid, unexpectedly increased respiratory frequency unaffected by naloxone. These findings highlight critical pharmacological differences between kratom-related alkaloids, emphasizing potential risks associated with products containing high concentrations of 7-HMG.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 19
- FWCI
- 18.33
- Field percentile
- top 1%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel mitragynine analog with low efficacy mu-opioid receptor agonism displays antinociception with attenuated adverse effects
S. Chakraborty, J. F. Diberto, … s. majumdar·bioRxiv·Apr 22, 2021
- Fentanyl depression of respiration: comparison with heroin and morphine
R. Hill, R. Santhakumar, … G. Henderson·bioRxiv·Jun 6, 2019
- Negative allosteric modulation of the μ-opioid receptor
E. S. O'Brien, V. A. Rangari, … B. K. Kobilka·bioRxiv·Sep 8, 2023
- Xylazine exacerbates fentanyl-induced respiratory depression and prevents rescue by naloxone in mice
Joshua M. Watkins, Rachel Hahn, … Andrea G. Hohmann·PsychopharmacologyPeer-reviewed·Mar 23, 2026
- The NMDAR positive allosteric modulator NYX-783 selectively blocks opioid withdrawal conditioned place aversion in mice.
Richard Trinko, Ethan P. Foscue, … Ralph Dileone·bioRxiv·Sep 25, 2025
- Melanocortin receptor 4 agonist setmelanotide treats opioid-induced respiratory depression
Mateus R. Amorim, Noah R Williams, … Vsevolod Y. Polotsky·bioRxiv·Mar 10, 2026